These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 25525)

  • 1. [Hydroxyproline in the dialysate as a parameter of secondary hyperparathyroidism. Effects of phosphate reduction and alkalization].
    Schiessl JH; Schweigart U; Bottermann P; Kopp KF
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1310-3. PubMed ID: 25525
    [No Abstract]   [Full Text] [Related]  

  • 2. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Features of correction of phosphate-calcium metabolism disorders in terminal renal failure].
    Pilotovich VS; Romanovich VP; Shilaĭ LM; Tukaĭ NN
    Klin Med (Mosk); 1992; 70(3-4):49-51. PubMed ID: 1507848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 7. Iminoacidopathy in renal failure.
    Simon NM; Bell NH; Del Greco F
    Arch Intern Med; 1970 Feb; 125(2):299-301. PubMed ID: 5412018
    [No Abstract]   [Full Text] [Related]  

  • 8. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].
    Gallar P; Ortega O; Gutiérrez M; Muñoz M; Hilara L; Oliet A; Rodríguez I; Giménez E; Vigil A
    Nefrologia; 2000; 20(4):355-61. PubMed ID: 11039261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 10. [Radioimmunologic determination of circulating parathyroid hormone in patients with primary and secondary hyperparathyroidism].
    Lo Giudice C; Cascone C; Manente P; Gasparoni P; De Luca M; Rota G; Conte N
    Minerva Med; 1982 Dec; 73(48):3425-8. PubMed ID: 7177469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
    Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
    Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Usefulness of calcium acetate as a chelating of phosphorus in patients in hemodialysis with secondary hyperthyroidism].
    Torregrosa Prats JV; Mas Mas M; Montesinos Ballestena M; Casellas Bartumeus J; Campistol Plana JM
    An Med Interna; 1995 Aug; 12(8):377-81. PubMed ID: 8924527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resolution of secondary hyperparathyroidism after cadaveric renal allograft.
    Varghese Z; Wills MR; Ahmed KY; Fairney A; Baillod RA; Tatler GL; Hopewell JP; Moorhead JF
    Proc Eur Dial Transplant Assoc; 1975; 11():261-7. PubMed ID: 1105549
    [No Abstract]   [Full Text] [Related]  

  • 14. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
    Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
    J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of subtotal parathyroidectomy in patients on haemodialysis].
    Vujić D; Majster Z; Lazić N; Radmirović A; Kekić Z
    Srp Arh Celok Lek; 1994; 122(1-2):34-7. PubMed ID: 17972801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ultrastructural localization of aluminum in the parathyroid cells of patients on chronic dialysis].
    Galle P; Campos H; Giudicelli C
    C R Seances Acad Sci III; 1983; 296(12):545-50. PubMed ID: 6409363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium carbonate. A better phosphate binder than aluminum hydroxide.
    Lerner A; Kramer M; Goldstein S; Caruana R; Epstein S; Raja R
    ASAIO Trans; 1986; 32(1):315-8. PubMed ID: 3535845
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.
    Sawyer N; Noonan K; Altmann P; Marsh F; Cunningham J
    Nephrol Dial Transplant; 1989; 4(2):105-9. PubMed ID: 2496350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phosphate binders for therapy of hyperphosphatemia causing secondary hyperparathyroidism and renal osteodystrophy in patients with chronic renal failure].
    Kanagawa S; Yosikawa Y; Dohi Y
    Nihon Rinsho; 1991 Dec; 49 Suppl():770-4. PubMed ID: 1808348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.